Latest research on Ustekinumab

CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis.

Latest findings

More partial responders at week 28 who received Ustekinumab 90 mg every 8 weeks achieved PASI 75 at week 52 than did those who continued to receive the same dose every 12 weeks. [source, 2009]
Authors concluded that intensification of dosing to once every 8 weeks with Ustekinumab 90 mg might be necessary to achieve a full response. [source, 2009]
In a phase III, double- blind, placebo- controlled study, 766 patients with moderate- to- severe psoriasis (PHOENIX 1) were given Ustekinumab 45mg or 90mg subcutaneously at weeks 0 and 4 and then every 12 weeks. [source, 2009]
It was found that Ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate-to-severe plaque psoriasis through one year. [source, 2009]
In another study (PHOENIX 2) 70% patients with moderate-to-severe plaque psoriasis, receiving two subcutaneous doses of Ustekinumab, had a 75% reduction in psoriasis at week 12. [source, 2009]
Both studies showed that Ustekinumab could control plaque psoriasis with only four injections a year resulting in greater ease of use and more sustained relief. [source, 2009]
The effect of Ustekinumab, a monoclonal anti-p40 antibody, was examined recently in a randomised double-blind placebo-controlled crossover clinical trial including 146 patients with PsA refractory to non-steroidal anti-inflammatory drugs, classical DMARDs, or TNF-α antagonists. [source, 2009]
The results were still significant but more modest when using more stringent criteria such as ACR50 and ACR70 with 25% and 11% in the Ustekinumab versus 7% and 0% in the placebo groups achieving these response rates, respectively. [source, 2009]
The effect on psoriasis seemed stronger than on arthritis as 52% and 33% in the Ustekinumab and 5% and 4% in the placebo groups achieved improvements of 75% and 90% in psoriasis area and severity index (PASI), respectively [109]. [source, 2009]